Novocure's lung cancer therapy succeeds in late-stage trial
March 27 (Reuters) - Novocure NVCR.O said on Wednesday that its cancer therapy met the main goal of a late-stage trial testing it as a treatment for a type of lung cancer. (Reporting by Puyaan Singh in Bengaluru; Editing by Shounak Dasgupta) ((Puyaan.Singh@thomsonreuters.com))
Recent news on NovoCure
See all newsOncology firm Novocure says cyberattack exposed US patient records
Novocure Ltd reports results for the quarter ended June 30 - Earnings Summary
Novocure Q2 revenue beats, lifts 2026 outlook
Brief: Novocure Q2 Revenue USD 183.584 Million Vs. IBES Estimate USD 172.4 Million
U.S. STOCKS ON THE MOVE-Kardigan, Energy companies, Take-Two, Accenture